Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management

Cited by (508)

Items 401–500 of 508

1. Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third‐Line or Later Relapsed/Refractory Multiple Myeloma
   Joshua Ryan Richter, Yvonne Adeduni Efebera, Habte Aragaw Yimer, Pragya Shukla, Venediktos Kapetanakis, Molly F. Purser, Natalie N. Boytsov, N L Ballew · 2026 · American Journal of Hematology
2. Awareness and Utilization of the Revised Second International Staging System ( R2 ‐ ISS ) and 1q21 Gain/Amplification Testing: A Nationwide Web‐Based Survey of Hematologists in Japan
   Nami Tagami, Heigoroh Shirai, Ichiro Hanamura · 2026 · Cancer Medicine
3. The LUMINA Framework: Development of a Theory-Informed Conceptual Model for Chronic Uncertainty and Treatment Burden in Lymphoid Neoplasms
   Anna Fleischer · 2026 · Lymphatics
4. Safety profile of chimeric antigen receptor T‐cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta‐analysis of proportions from clinical trials
   Charalampos Filippatos, Ioannis Ntanasis‐Stathopoulos, Areti Voulomenou · 2026 · British Journal of Haematology
5. Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
   Jessica McElwee, Grace Elsey, Rebecca M. Gonzalez et al. · 2026 · American Journal of Hematology
6. Multi-center validation of a machine learning model for early detection of monoclonal immunoglobulin-related disorders using routine laboratory data
   Yu Hu, Xiaoyan Hao, Xiaoyan Li et al. · 2026 · Frontiers in Immunology
7. Structural and functional characterization of Acyl-CoA Synthetase Long-Chain Family Member 3 (ACSL3) and its targeted inhibition by gramicidin in multiple myeloma
   Yanhua Yue, Wenjing Du, Yingjie Miao, Fang Wang, Luo L, L Peng C Yan, Yang Cao, Yuqing Qi, Kefeng Li, Ying Liu et al. · 2026 · International Journal of Biological Macromolecules
8. Cost-Effectiveness of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Aged 65 to 69 Years (CAREMM-2110 Study)
   Jung Yeon Lee, Seungpil Jung, Sung‐Soo Park · 2026 · Value in Health
9. Modelos de estadificación del riesgo e imputación de datos en mieloma múltiple. Una revisión narrativa de la literatura
   Eliana Andrea González Artunduaga, Kenny Gálvez, Nelson Alirio Cruz Gutierrez, Simón Sandoval-Álvarez, Fabián Steven Beltrán Anguita, Sofía Elizabeth Muñoz Medina · 2026 · Revista Colombiana de Hematología y Oncología
10. Efficacy of exercise interventions in multiple myeloma: a systematic review and meta-analysis
    Luis Polo-Ferrero, Javier Martín-Vallejo, María Victoria Mateos-Manteca, Andrea Calleja Caballero, Sara Marcos-Asensio, Ana Silvia Puente-González, Eduardo José Fernández Rodríguez, Roberto Méndez Sánchez, Carlos Martín-Sánchez, Jesús Pérez et al. · 2026 · Journal of Cancer Survivorship
11. Efficiency of Automated and Manual Plasma Cell Immunoselection for FISH Analysis in Multiple Myeloma
    Helena Podgornik, Katarina Reberšek · 2026 · International Journal of Laboratory Hematology
12. Bortezomib-induced gastrointestinal dysfunction, peripheral neuropathy and neuroimmune signalling are influenced by the gut microbiota in mice
    Jacqui S. Scott, Sadia Munir, Miriam Anne Lynn, Jvaughn Duggan, Joel Castro, Andrea M. Harrington, Stuart M. Brierley, Gudrun Schober, Kathy Cash, Bernice Gutschmidt et al. · 2026 · Journal of Neuroinflammation
13. Advances in Modeling Multiple Myeloma Within the Bone Marrow Tumor Microenvironment for Exploration of Current and Emerging Therapies
    Charlotte E. Toomes, Giles Best, Timothy Hollenberg, Rose Turner, Claudine S. Bonder, Barbara J. McClure · 2026 · Cancers
14. A Rare Case of Plasmablastic Myeloma With Dual Kappa and Lambda mRNA Expression Presenting as a Solitary Hard Palate Tumor
    Ken Tanaka, Masaki Hasegawa, Akira Katsumi · 2026 · Cureus
15. An Unusual Presentation of Plasma Cell Myeloma with Multiple Extramedullary Soft- Tissue Swellings: A Case Report
    Parackrama Karunathilake, Naveen Abeysinghe, Sanjeewa Bowatte, Prabhashini Kumarihamy, Dushantha Madegedara, Harshani Karunarathna, Kaveesha Katugahage, Vihanga Mallikarachchi, Anusha Gardhiyawasam, Iresha Rajapaksha · 2026 · Research Square
16. MYBL2 Knockdown Enhances Ferroptosis and Bortezomib Sensitivity by Transcriptionally Regulating CDKN3 and Inactivating PI3K/Akt Signaling in Multiple Myeloma
    Ping Wang, T C Liu, Xin Xiong · 2026 · Journal of Biochemical and Molecular Toxicology
17. Kidney Transplantation Post–Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma
    Zahraa Khan, Darshana M. Dadhania, Eugène Brailovski, Heather Jolie Landau, Aisha Shaikh · 2026 · American Journal of Kidney Diseases
18. Correlation Between SGK1 Expression Level and Multiple Myeloma Progression After Autologous Hematopoietic Stem Cell Transplantation
    Ting Fan, Caili Guo, Ying Zhang · 2026 · Biochemical Genetics
19. Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis
    Ivan J. Huang, Grace Baek, Qian Vicky Wu et al. · 2026 · Bone Marrow Transplantation
20. Multiple myeloma: A tale of deregulated transcription factors
    Nahia Gómez-Echarte, Edurne San José‐Eneriz, E. Compains, Paula Rodríguez‐Otero, Felipe Prósper, Xabier Agirre · 2026 · HemaSphere
21. Связь AL-амилоидоза и множественной миеломы: необходимость ранней диагностики и агрессивной терапии в современной клинической практике
    Е. В. Зуховицкая, В.Ю. Пинчук, И.А. Искров · 2026 · Гематология Трансфузиология Восточная Европа
22. A clinical dilemma for treatment choice of extramedullary spinal plasmacytoma in patients with multiple myeloma: chemotherapy or surgery? A double-case clinical report
    Tetiana V. Lymanets, Ганна Сергіївна Маслова, Y.O. Stadnik, Iuliia Gusachenko, Oleksandr Havlovskyi · 2026 · Ukrainian Neurosurgical Journal
23. Periplocin targets STAT3 to suppress MYC expression and inhibit multiple myeloma cell proliferation
    Rong-fang Wei, Jingxian Chen, Shu-Ping Lai, Zi-ang Chen, Yan-ying Zhou, Ya-ping Liao, Yan Chen · 2026 · Journal of Chinese Integrative Medicine
24. Natural killer cells from patients relapsing on daratumumab therapy express an exhausted-associated phenotype
    Katrine Fladeland Iversen, Line Nederby, Thomas Lund, Trine Andreasen Leth, Torben Plesner · 2026 · Clinical Hematology International
25. Clinicopathologic characterization of plasma cell neoplasms with IGH :: CCND3
    Nandan Padmanabha, Adam Samuel Sperling, Elizabeth A. Morgan, Phillip D. Michaels, Sam Sadigh · 2026 · American Journal of Clinical Pathology
26. Therapy update: An introduction to the pharmacology, safety, and efficacy of bispecific antibodies in relapsed or refractory multiple myeloma
    Dawud Ellayan · 2026 · American Journal of Health-System Pharmacy
27. Perioperative considerations for patients with multiple myeloma
    Tracy Kallenbach · 2026 · European Journal of Anaesthesiology Intensive Care
28. Long-period grating optical fiber sensor for IgG-type monoclonal protein measurement
    Peizhou Wu, Stephen P. Morgan, Ricardo Correia · 2026 · Frontiers in Bioengineering and Biotechnology
29. Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy
    Frederik Herzberg, Feiteng Lu, Michael Korenkov, Vincent Fregona, Carin Didoss, Nina Heisterkamp, Maximilian Sprechert, Alexandra Polici, Clarissa Heck, Simon F. Haas et al. · 2026 · Leukemia
30. BCMA-targeted therapy enables combined haploidentical stem cell and kidney transplantation in a highly sensitized patient
    Kassem Safa, Vikram Pattanayak, Andrew Jenho Yee, Yi‐Bin Chen · 2026 · American Journal of Transplantation
31. Circulating Tumor DNA in Multiple Myeloma: Current Insights and Future Perspectives
    Aleksandra Sretenovic, Marko Mitrovic, Nikola Vukosavljevic · 2026 · Biology
32. The Prognostic Value of Combined Complete Blood Count and Immune Cell Profiling in Patients with Multiple Myeloma Treated with Chemotherapy Sequential Transplantation
    Jiang Zhang, Yuehua Chen, Yizhi Mao, Yuehua Chen, Mengzhi Hong, Junxun Li, Juan Ouyang · 2026 · Cancers
33. The Effect of Self-Rehabilitation on Physical Fitness in Adults with Hematological Malignancies (HMs) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
    Michał Chmielewski, Agnieszka Szeremet, Paula Jabłonowska-Babij · 2026 · Cancers
34. Activating RARβ to overcome immunomodulatory drug resistance in t(4;14) human myeloma
    Ling Zhong, Qiang Wang, Miao Xian et al. · 2026 · Leukemia
35. Hematological malignancies
    Velizar Stefanov Shivarov · 2026 · Elsevier eBooks
36. Clinical Outcomes of Acute Pancreatitis in Patients With Multiple Myeloma
    Hala Soomro, Amninder Singh, Mohammad Ahsen Soomro · 2026 · ONCOLOGY
37. Un myélome multiple atypique à ne pas prendre à la légère !
    Marine Jaillard, Julie Milandri, Magali Dechomet · 2026 · Revue Francophone des Laboratoires
38. Cardiovascular Care in Multiple Myeloma: A Comprehensive Review and Integrated Systems-Based Approach from a UK Cardio-Oncology Centre of Excellence
    Daniel Akrawi, Shayan Datta, Suzan Hatipoğlu, Ashutosh D. Wechalekar, Aruni Ghose, Ahmed Alkhateeb, John Malcolm Walker, Arjun Kumar Ghosh · 2026 · Current Cardiology Reports
39. Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis
    Yubiao Pan, Yue Wang, Yaqin Xiong, Panpan Li, Chenqi Yu, Peng Liu · 2026 · Hematological Oncology
40. Ferroptosis in multiple myeloma: molecular mechanisms and therapeutic opportunities
    Wanfu Jiang, Li Xu, Changling Zhu, Guangqiang Bai, Sihao Peng, Na Ma · 2026 · Frontiers in Oncology
41. Prognostic and biological significance of MRPL13 in multiple myeloma: evidence from multi-cohort, single-cell analyses
    Wanyi Liu, Changjian Yan, Huiqiang Wu, Chaoling Wu, Zhiyin Cai, Zechuan Wang, Wei-Huang Zhuang, Meiling Li, Jianxin Guo · 2026 · Frontiers in Oncology
42. SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver
    Roisin M. McAvera, Izabela Cymer, John Quinn, Philip Thomas Murphy, Patrick Thornton, Niamh McAuley, Harmony Black, Omar Abdelzaher, Catherine Duane, Tatiana Cichocka et al. · 2026 · European Journal Of Haematology
43. Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myeloma
    Ji Luo, Yeon‐Hwa Lee, Christophe Cataisson, Haibo Zhang, Snehal M. Gaikwad, Wendy Dubois, Aleksandra A Michalowski, Howard Hua Yang, Thomas Joshua Meyer, Ryan Young et al. · 2026 · Research Square
44. Recurrent Radiculopathy Caused by an Epidural Cervical Plasmacytoma Revealing Plasma Cell Leukemia: A Case Report and Literature Review
    Luis Garibay, José-Carlos Sauri-Barraza, Eduardo Callejas Ponce · 2026 · Cureus · Retracted
45. Sparse integrative dictionary learning resolves conserved drug-response states in multiple myeloma (MM)
    Mingke Wu, Jin Lu, Qing Ge · 2026 · Cancer Genetics
46. PD-L1+ exosomes as biomarkers and therapeutic targets in multiple myeloma: implications for CAR-T efficacy and combination immunotherapy
    Peng Xu, Wen-Jie Yu, Si‐Han Wu et al. · 2026 · Biomarker Research
47. Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye
    Aslı Bozdemir, Sibel Hacıoğlu, Gülsüm Akgün Çağlıyan et al. · 2026 · Journal of Clinical Medicine
48. Cytogenetics and FISH in Hematologic Malignancies
    D.S. Udayakumar, Bhawna Jha, Akshay Ramesh Gore · 2026 · Springer eBooks
49. Multiple Myeloma: Risk Stratification and Management
    Gurleen Oberoi, Rajiv Kumar · 2026 · Springer eBooks
50. Real-World Diagnostic Yield and Longitudinal Dynamics of Fluorescence In Situ Hybridization in Hematologic Malignancies: A Five-Year Retrospective Analysis of 1357 Patient Samples
    Rosalba Fumo, Katia Scala, Sara Gaeta et al. · 2026 · Genes
51. 2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group
    Meral Beksaç, Metban Güzel Mastanzade, Başak Bostankolu Değirmenci, Beyza Oluk, Buğra Sağlam, Dilek Özden Özlük, Esra Cengiz, Fadime Nurcan Alhan, Hatice Zeynep Dikici, Kübra Yel Uygun et al. · 2026 · Clinical Lymphoma Myeloma & Leukemia
52. Chromosome 1q alterations in transplant-eligible multiple myeloma: clinical impact of copy number and co-occurring high-risk cytogenetic features
    Irene Straßl, Daniel Bindeus, Jonathan Burghofer, Martin Erdel, Veronika Buxhofer‐Ausch, Sigrid Machherndl‐Spandl, Olga Saini, Dagmar Wipplinger, Emine Kaynak, Robert Milanov et al. · 2026 · Frontiers in Oncology
53. Lymphomas
    Gulden Diniz, Ali İhsan Gemici · 2026 · Springer eBooks
54. Simvastatin as an immunomodulator and anti-myeloma agent – epidemiological, in vitro and murine model studies
    Aharon Lion, Arieh Y. Israel, Eugene Merzon, Howard S. Oster, Abraham Weizman, Galia Luboshits, Bjarne Bogen, Moshe Mittelman, Michael A. Firer · 2026 · Frontiers in Immunology
55. Drug Resistance in Multiple Myeloma: Tumor‐Intrinsic Mechanisms and the Bone Marrow Microenvironment
    Yixuan Chen, Wenming Huang, Mingxuan Tang, Xiaotao Wang · 2026 · Cell Biochemistry and Function
56. Single-cell and bulk transcriptomic profiling of M2-like tumor-associated macrophages reveals a prognostic signature and an inflammation–metabolism crosstalk program in multiple myeloma
    Hui Zhao, Jing Kang, Huiling Ouyang · 2026 · Translational Oncology
57. Real-world efficacy and safety of the carfilzomib–pomalidomide–dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study
    Huishou Fan, XiangYan Feng, Rongxia Wei, Xin Zhang, Tianlan Li, Lu Liu, Hui Wang, Lingjie Sun, Xue Shi, Hongguo Zhao et al. · 2026 · Therapeutic Advances in Hematology
58. Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse‐Risk Subtype in AL Amyloidosis With Inferior Long‐Term Survival
    Tamer Hellou, Estefania Gauto Mariotti, Ahmed Alnughmush et al. · 2026 · American Journal of Hematology
59. Comprehensive Analyses of SOX7 Provide Novel Insights on Its Tumor Suppressor Role and Its Target Genes with Therapeutic Implications in Multiple Myeloma
    Arda Ceylan, Xiaozhou Hu, Tevfik Hatipoğlu, Fenangi Chiara Nainkwi, Bahriye Payzın, Güner Hayri Özsan, Itır Şirinoğlu Demiriz, Ömer Şeker, Merve Kakci, Osman Can Öztürk et al. · 2026 · International Journal of Molecular Sciences
60. Consensus-based recommendations by the Hematology Society of Taiwan for the management of multiple myeloma in 2026
    Yu-Chin Hung, Shih‐Feng Cho, Yi-Yang Chen, Ya‐Ting Hsu, Shang‐Yi Huang, Chao‐Hung Wei, Chun‐Kuang Tsai, Wei‐Han Huang, Chia‐Jen Liu · 2026 · Journal of the Formosan Medical Association
61. Development and validation of a generalizable M-protein screening model using routine laboratory indicators: a multicenter retrospective study
    Hou‐Long Luo, Lanxin Zhou, Hua Xiao, Qinxin Zhang, Xin Li, Jiahui Ye, Youlin Liu, Jin Li, Yonggang Liang, Anping Xu et al. · 2026 · Clinica Chimica Acta
62. Improving diagnostic strategies for plasma cell dyscrasias: a laboratory perspective on Bence Jones proteinuria
    Paolo Amedeo Tillio, Yasaman Lotfolahzadeh, Vesselina Kroumova, Chiara Puricelli, Paola Boggione, Elisabetta Mairate, Andrea Mora, Roberto Serino, Elena Saliva, Maria Giovanna Sulas et al. · 2026 · Clinica Chimica Acta
63. Associations Between Routine Laboratory Indicators and Clinical Risk Stratification in Newly Diagnosed Multiple Myeloma: A Retrospective Study
    Huijuan Yang, Guixiu Luo, Huihan Zhao · 2026 · Research Square
64. Primary Plasma Cell Leukemia
    Mahin Bhatt, Saurabh Zanwar, Shaji Kunnathu Kumar, S. Vincent Rajkumar · 2026 · American Journal of Hematology
65. Immediate and late results of autologous hematopoietic stem cell transplantation: the experience of the P. A. Herzen Moscow Oncology Research Institute (2020–2025)
    С. В. Семочкин, Alevtina M. Chervontseva, М. А. Вернюк, В. В. Лунин, A A Tarasenkova, Mobil Akhmedov, И. В. Черкашина, L. S. Khayrullina, Elena R. Nemtsova, Yu B Venediktova et al. · 2026 · Oncohematology
66. Evaluation of the UK Myeloma Research Alliance risk profile in transplant‐ineligible multiple myeloma patients treated with novel agents
    Hitomi Nakayama, Tomonori Nakazato, Atsushi Takahata et al. · 2026 · British Journal of Haematology
67. Late-onset isolated cutaneous histoplasmosis after autologous stem cell transplant in high-risk kappa light-chain myeloma with del(17p13)
    Bibhant Shah, Kavya Ronanki, Prisla Maria Dalton · 2026 · Skin Health and Disease
68. BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and meta‐analysis guiding treatment selection
    Qi Liang, Shutong Liu, Chunhua Li, Zhijian Liang, Lianxin Zhu, Weida Wang, Zhongjun Xia, Limei Zhang, Yang Liang, Yun Wang · 2026 · British Journal of Haematology
69. From toxicity to immunity: Evaluating CAR-T and conventional therapies in multiple myeloma through quality-adjusted life year (QALY) outcomes
    Guluzar Gulnur Itez, Asuman Sunguroğlu · 2026 · Therapeutic Advances in Hematology
70. Integrating Palliative Care into Relapsed/Refractory Multiple Myeloma in the Immunotherapy Era: A Narrative Review
    Muhanad Alzahrani, Zaid Musaad Alsharif, Ziyad Alzahrani · 2026 · Journal of Pain & Palliative Care Pharmacotherapy
71. Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma
    Yating Li, Lihui Shi, Wenqiang Yan, Yuntong Liu, Jian Cui, Jingyu Xu, Jieqiong Zhou, Chenxing Du, Shuhui Deng, Weiwei Sui et al. · 2026 · Leukemia
72. Xuanbi Xiaoliu formula alleviates bone destruction by targeting the CREBBP/c-Myc axis with saponarin in multiple myeloma
    Jinjun Qian, Jiale Zhang, Zhendong Deng, 戈小洁, Cheng Wang, Shanliang Sun, Xichao Yu, Hongjie Wu, Xiangtu Kong, Jinrui Wei et al. · 2026 · Phytomedicine
73. Clinical guidance on evaluation and management of bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS): an IOF position statement
    Cyrille B. Confavreux, Béatrice Bouvard, Robert Blank, Peyman Hadji, Emmanuel Biver, Jean‐Jacques Body, Maria Luisa Brandi, Claudia Campusano, Peter Robert Ebeling, A. El Maghraoui et al. · 2026 · Osteoporosis International
74. Routine Laboratory-Based Machine Learning for Discriminating Multiple Myeloma from Clinical Mimickers: Development and Internal Validation of a Diagnostic Prediction Model
    Batuhan Erdoğdu, Duygu GÜL, Berrak Itır Aylı · 2026 · Diagnostics
75. Patient-derived mesenchymal stromal cells establish an IL-6 axis that marks progression from smouldering to active multiple myeloma
    P Blair, Tianyuan Chu, Andrew Robinson, Khalid Saja, Stuart A. Rushworth, Ralf Michael Zwacka, Andrea Mohr · 2026 · Cytokine
76. Changing Patterns of Causes of Death in Patients With Multiple Myeloma During the Modern Therapeutic Era
    Abel Rosado-Rodriguez, Esther Ortega-Vida, Antonio Cárdenas-Cruz · 2026 · Clinical Lymphoma Myeloma & Leukemia
77. Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation
    Santosh Gautam, Laura Morrison, Philippe Thompson‐Leduc · 2026 · Journal of Managed Care & Specialty Pharmacy
78. Other primary malignancies are associated with inferior survival in multiple myeloma: a single-center matched retrospective cohort study
    Changnian Li, Yaru Wang, Lulu Li · 2026 · Frontiers in Oncology
79. Combined vitamins D3 and K2 as potential modulators of multiple myeloma cell pathophysiology: transcriptomic and epigenetic effects under standard culture and bone marrow-like conditions
    Karolina Łuczkowska, Patrycja Stodolak, P. Kulig, B. Machaliński · 2026 · Frontiers in Oncology
80. Matched marrow and blood profiling reveals compartment- and feature-specific liquid-biopsy signals in multiple myeloma
    Dor David Abelman, Jenna Eagles, Stephanie Pedersen et al. · 2026 · medRxiv
81. A Comparative Analysis of Multiple Myeloma Disease Burden in China and Globally From 1990 to 2023 and Future Trend Projections
    Fuhong Zhu, Huiting Wang · 2026 · Cancer Medicine
82. Salvage Autologous Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma: Long-Term Efficacy and Safety Outcomes from a Single-Center Real-World Cohort
    Gülten Korkmaz, Funda Ceran, Simten Dağdaş et al. · 2026 · Journal of Clinical Medicine
83. Two decades of progress, persistent inequity: national trends in multiple myeloma mortality in the United States, 1999–2024
    Mohammad Eisa Ali, Federico Ferrari, Ali Shan Hafeez, Anusha Akram, Muhammad Hassaan Javaid, Maleeha Pandit, Hannah Mushtaq · 2026 · Cancer Causes & Control
84. Carfilzomib preserves dendritic cell phenotype and function compared with bortezomib
    L. Wang, M. Dahlfrancis, Daniela Dörfel, J.S. Walz, Martin G. Klatt, Frank Grünebach, Susanne Malaika Rittig · 2026 · Frontiers in Immunology
85. Молекулярно-генетические и цитогенетические предикторы клинического течения впервые диагностированной множественной миеломы
    Е. Н. Мисюрина, Д. С. Поляков, А. А. Солодовник, Е. Н. Зотина, Т. Н. Толстых, A. А. Akhmadeeva, Владимир Николаевич Якимец, Т. С. Чуднова, Л. А. Кесаева, А. С. Мкртчан et al. · 2026 · Гематология. Трансфузиология. Восточная Европа
86. Long-Term Progression-Free Survival in Patients Treated With RVD Induction and Risk-Adapted Maintenance
    Lilly ChunHong Gu, Om Raval, Xiyuan (Angel) Ji, Nisha Joseph, Craig C. Hofmeister, Vikas Anand Gupta, Richa Parikh, Nishi Shah, Roberto Mina, Jeffrey M. Switchenko et al. · 2026 · Clinical Lymphoma Myeloma & Leukemia
87. Renal Impairment in Multiple Myeloma: Pathophysiology, Diagnosis and Therapeutic Approaches
    Ionela Rotaru, Alina Daniela Tanase, Ana Maria Pătraşcu · 2026 · IntechOpen eBooks
88. Artificial intelligence in risk stratification and therapeutic decision-making for multiple myeloma: Recent advances and future directions
    Yongrui Zhang, Xianghong Jin, Junling Zhuang · 2026 · Intelligent Medicine
89. Apparent vitamin D intoxication due to paraprotein interference
    Sjaam Jainandunsing, Evert F S van Velsen, Pauline Verschuure · 2026 · JCEM Case Reports
90. Comparison of non-cryopreserved and cryopreserved autologous hematopoietic stem cell transplantation among patients with myeloma: single-center experience
    Lazar Chadievski, Milche Cvetanoski, Sonja Genadieva Stavrikj et al. · 2026 · Frontiers in Oncology
91. Population-based study of newly diagnosed multiple myeloma in Moscow: data from the Moscow City Cancer Registry (2022–2025)
    Elena N Misyurina, Е. Н. Зотина, Natalia G. Chernova et al. · 2026 · Oncohematology
92. Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
    Sagar Lonial, Meletios Athanasios Dimopoulos, Μαρία Γαβριατοπούλου, Kihyun Kim, Chang-Ki Min, Albert Oriol, Catarina Campos Costa Moreira, Hang Quach, Lugui Qiu, Zhongjun Xia et al. · 2026 · The Lancet Oncology
93. Tailoring Therapy for Frail and Elderly Myeloma Patients
    Thomas George, Raphael Elie Szalat · 2026 · The Cancer Journal
94. Bilateral proptosis as the initial manifestation of multiple myeloma with orbital involvement: case report and literature review
    Sarra Chadli, Maamar Mouna, Hajar Khibri, Wafa Ammouri, Naima Moatassim, Hamza Retal, Zoubida Mezalek Tazi, H. Harmouche · 2026 · Oxford Medical Case Reports
95. Chronic pure red cell aplasia developed in a patient with multiple myeloma treated with lenalidomide
    Hiroto Kaneko, Reiko Isa, Mihoko Yoshida · 2026 · Journal of Hematology and Allied Sciences
96. Pre-transplant depressive symptoms and exploratory psychosocial associations among patients with multiple myeloma who underwent autologous hematopoietic stem cell transplantation: A cross-sectional secondary analysis
    María Constanza Benavides Cáceres, Elia Francisca Espinoza de Avila, Martha Georgina Ochoa Madrigal, Óscar Meneses Luna, Luara Luz Arana-Luna, Mario Antonio Téllez González, Deldhy Nicolas Moya-Sánchez · 2026 · Inquisiva Open
97. Current Evidence for Integrating Mass Spectrometry into Clinical M-Protein Assessment in Plasma Cell Dyscrasias
    Louis Nevejan, Louisiane Courcelles, Martine Vercammen · 2026 · Clinical Chemistry
98. Belantamab mafodotin triggers immune invigoration in multiple myeloma via inflammatory and immunogenic cell death
    Edmund C. R. Watson, Halima Ali Shuwa, Morgan W. D. Heycock, Jennifer Wade, Chen-Yi Wang, Mint Htun, Lingzi Li, Vivianne Niehaus, Warren Baker, Benjamin Miller et al. · 2026 · BMJ Immunology
99. Single-Cell and Multi-Omics Profiling of the Multiple Myeloma Immune Niche: From Bone Marrow Architecture and Metabolic Reprogramming to Immunotherapy Response
    Katia Beider, Olga Ostrovsky, Arnon Nagler · 2026 · Cancers
100. Characterizing the landscape of hospitalizations for multiple myeloma in Spain: a retrospective analysis (2016–2023)
     Ane Brieva López, Maria Ordoñez-Garcia, Mariana Cerrato-Salas · 2026 · Leukemia & lymphoma/Leukemia and lymphoma